Zafgen Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
36.81 M |
Public Float |
13.92 M |
Zafgen Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.73 |
Market Cap |
$46.29 M |
Shares Outstanding |
37.33 M |
Public Float |
32.81 M |
Address |
175 Portland Street Boston Massachusetts 02114 United States |
Employees | - |
Website | http://www.zafgen.com |
Updated | 07/08/2019 |
Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders. It offers the ZGN-1061, a novel fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is currently being profiled for its utility in the treatment of type 2 diabetes. The company was founded on November 22, 2005 and is headquartered in Boston, MA. |